New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:08 EDTTXMDTherapeuticsMD receives enrollment approval for Phase 3 trial of TX 12-001HR
TherapeuticsMD announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.
News For TXMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
17:02 EDTTXMDTherapeuticsMD files $100M mixed securities shelf
Subscribe for More Information
December 15, 2014
16:19 EDTTXMDTherapeuticsMD receives five new patent allowances
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use